New York State Common Retirement Fund Has $9.33 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

New York State Common Retirement Fund lowered its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 0.2% during the fourth quarter, HoldingsChannel reports. The fund owned 315,502 shares of the medical device company’s stock after selling 684 shares during the quarter. New York State Common Retirement Fund’s holdings in Tandem Diabetes Care were worth $9,333,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. RiverPark Advisors LLC acquired a new position in Tandem Diabetes Care in the 4th quarter valued at approximately $27,000. Signaturefd LLC increased its holdings in Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after purchasing an additional 1,517 shares during the period. PNC Financial Services Group Inc. raised its position in Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after purchasing an additional 1,099 shares during the last quarter. Creative Financial Designs Inc. ADV acquired a new position in Tandem Diabetes Care during the 4th quarter worth about $104,000. Finally, Stonebridge Capital Advisors LLC bought a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at about $112,000.

Wall Street Analyst Weigh In

TNDM has been the topic of several analyst reports. Citigroup upped their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $34.00 to $45.00 in a report on Thursday, April 25th. Stifel Nicolaus increased their price target on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Wells Fargo & Company raised Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $21.00 to $45.00 in a research note on Monday. Finally, Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.82.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock opened at $36.20 on Thursday. The business has a 50-day simple moving average of $31.74 and a 200 day simple moving average of $25.82. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -10.52 and a beta of 1.12. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. Tandem Diabetes Care, Inc. has a one year low of $13.82 and a one year high of $40.61.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. On average, research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.